New psoriasis drug enters first human testing
NCT ID NCT07254325
Summary
This early-stage study aims to see how a new version of a psoriasis drug, called CMAB015, compares to an already approved drug, Cosentyx. It will involve 114 healthy Chinese men who will receive a single injection. Researchers will track how the drugs move through the body, check for safety issues, and see if the body produces antibodies against them over 112 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.